

## HEPATOPROTECTIVE ACTIVITY OF MEDICINAL PLANTS: A COMPREHENSIVE REVIEW

Fathima M.<sup>1\*</sup>, Mohamed Fiaz A.<sup>1</sup>, Srinivasan P.<sup>1</sup>, Dhachinamoorthi D.<sup>2</sup>, Suhel Y.<sup>1</sup>

<sup>1</sup>Department of Pharmacology, Sree Abirami College of Pharmacy, Coimbatore, India.

<sup>2</sup>Department of Pharmaceutics, Sree Abirami College of Pharmacy, Coimbatore, India.



\*Corresponding Author: Fathima M.

Department of Pharmacology, Sree Abirami College of Pharmacy, Coimbatore, India.

DOI: <https://doi.org/10.5281/zenodo.20136073>

**How to cite this Article:** Fathima M.<sup>1\*</sup>, Mohamed Fiaz A.<sup>1</sup>, Srinivasan P.<sup>1</sup>, Dhachinamoorthi D.<sup>2</sup>, Suhel Y.<sup>1</sup> (2026). Hepatoprotective Activity Of Medicinal Plants: A Comprehensive Review. European Journal of Pharmaceutical and Medical Research, 13(5), 690–697.

This work is licensed under Creative Commons Attribution 4.0 International license.



Article Received on 15/04/2026

Article Revised on 05/04/2026

Article Published on 11/05/2026

### ABSTRACT

Liver diseases are a significant global health concern, contributing substantially to morbidity and mortality. Conventional pharmacological therapies often provide limited efficacy and may be associated with adverse effects, high costs, and incomplete recovery, prompting interest in alternative treatments. Medicinal plants, long used in traditional systems such as Ayurveda and Traditional Chinese Medicine, are rich in bioactive phytochemicals including flavonoids, alkaloids, terpenoids, phenolic compounds, and glycosides that confer hepatoprotective effects through antioxidant activity, modulation of inflammatory pathways, inhibition of fibrosis, enhancement of detoxification enzymes, and prevention of hepatocyte apoptosis. Key plants such as *Silybum marianum*, *Curcuma longa*, and *Phyllanthus niruri* have shown significant hepatoprotective potential in preclinical and clinical studies. However, limitations such as phytochemical variability, lack of standardization, and insufficient clinical evidence hinder their broader therapeutic application. This review highlights the mechanistic insights, experimental models, and clinical relevance of hepatoprotective medicinal plants, emphasizing the need for rigorous research to validate their efficacy and safety for integration into modern liver disease management.

**KEYWORDS:** Hepatoprotective, Medicinal Plants, Ethnopharmacology

### 1. INTRODUCTION

The liver is one of the largest and most metabolically active organs in the human body, playing a critical role in maintaining physiological homeostasis. It is involved in essential processes such as carbohydrate, lipid, and protein metabolism, detoxification of endogenous and exogenous substances, synthesis of plasma proteins, bile production, and storage of vitamins and minerals.<sup>[1]</sup>

Due to its central role in detoxification, the liver is continuously exposed to a wide range of harmful substances, including drugs, environmental toxins, alcohol, and infectious agents. This makes it highly vulnerable to injury, which can lead to acute or chronic liver diseases. Among these, hepatitis, liver cirrhosis, and nonalcoholic fatty liver disease represent major public health concerns globally.<sup>[2,3]</sup>

The pathogenesis of liver diseases is complex and multifactorial, involving oxidative stress, inflammation,

immune responses, and metabolic disturbances. Current therapeutic approaches are often limited in their ability to reverse liver damage and may be associated with significant side effects. For instance, long-term use of certain drugs can itself induce hepatotoxicity, further complicating treatment outcomes.<sup>[4,5]</sup>

In this context, medicinal plants have gained considerable attention as potential hepatoprotective agents. Traditional medicine systems have long utilized plant-based remedies for liver disorders, and modern scientific research has begun to validate these claims. The hepatoprotective effects of medicinal plants are primarily attributed to their rich phytochemical content, which provides antioxidant, anti-inflammatory, and cytoprotective properties.<sup>[6,7]</sup>

Furthermore, the increasing preference for natural therapies, coupled with their relatively lower cost and perceived safety, has fueled research into plant-derived

hepatoprotective compounds. However, scientific validation, standardization, and clinical evaluation remain essential for their integration into evidence-based medicine.<sup>[8]</sup>

## 2. PATHOPHYSIOLOGY

Liver damage occurs through a complex interplay of biochemical and molecular mechanisms, primarily involving oxidative stress, inflammation, and metabolic dysregulation.<sup>[9]</sup> These processes are often triggered by exposure to toxic substances such as Carbon Tetrachloride, Paracetamol, alcohol, and other xenobiotics.

One of the central mechanisms underlying liver injury is the generation of reactive oxygen species (ROS). These highly reactive molecules are produced during the metabolism of toxic compounds in hepatocytes. Excessive ROS production overwhelms the antioxidant defense system, leading to oxidative stress.<sup>[10]</sup>

Oxidative stress results in lipid peroxidation of cellular membranes, causing structural and functional damage to hepatocytes. It also affects proteins and DNA, leading to impaired cellular function and triggering apoptosis or necrosis. Mitochondrial dysfunction further exacerbates ROS production, creating a vicious cycle of cellular damage.<sup>[11]</sup>

Inflammation is another key component of liver injury. Activation of Kupffer cells (liver macrophages) leads to the release of pro-inflammatory cytokines such as TNF- $\alpha$ , IL-1 $\beta$ , and IL-6. These mediators promote further hepatocyte damage and contribute to the progression of liver diseases.<sup>[12]</sup>

Chronic liver injury can lead to fibrosis, characterized by excessive deposition of extracellular matrix proteins, particularly collagen. Over time, fibrosis progresses to cirrhosis, which is marked by irreversible structural changes, impaired liver function, and increased risk of liver failure and hepatocellular carcinoma.<sup>[13]</sup>

## 3. MECHANISMS OF HEPATOPROTECTIVE ACTIVITY

Medicinal plants exert hepatoprotective effects through multiple interconnected mechanisms:

### 3.1 Antioxidant Activity

One of the primary mechanisms is the scavenging of free radicals and reactive oxygen species. Phytochemicals such as flavonoids and phenolic compounds enhance endogenous antioxidant defenses, including glutathione, superoxide dismutase (SOD), and catalase.

### 3.2 Anti-inflammatory Effects

Medicinal plants inhibit inflammatory pathways by suppressing cytokines such as TNF- $\alpha$  and interleukins. They also modulate transcription factors like NF- $\kappa$ B, thereby reducing inflammation-induced liver damage.

### 3.3 Antifibrotic Effects

Certain plant compounds inhibit activation of hepatic stellate cells, which are responsible for collagen production. This prevents fibrosis and slows disease progression.

### 3.4 Detoxification Enhancement

Many plants stimulate phase I and phase II detoxification enzymes, enhancing the liver's ability to eliminate toxins. Activation of the Nrf2 pathway plays a key role in this process.

### 3.5 Anti-apoptotic Effects

Medicinal plants protect hepatocytes by regulating apoptosis-related proteins such as Bcl-2 and caspases, thereby preventing programmed cell death.

### 3.6 Immunomodulatory Effects

Some plants modulate immune responses, reducing autoimmune-mediated liver damage and enhancing overall hepatic resilience.

## 4. CURRENT TREATMENT OF LIVER DISORDERS

### 4.1 Pharmacological Therapy

Modern treatment strategies vary depending on the underlying cause of liver disease:

- Antiviral drugs for viral hepatitis
- Corticosteroids and immunosuppressants for autoimmune hepatitis
- Lipid-lowering and insulin-sensitizing agents for NAFLD
- Bile acids such as ursodeoxycholic acid for cholestatic disorders

However, many of these treatments are associated with limitations such as drug resistance, side effects, and incomplete recovery.

## 5. MEDICINAL PLANTS

Medicinal plants represent a rich source of hepatoprotective agents, many of which have been scientifically validated through experimental and clinical studies. These plants contain bioactive compounds that act synergistically to protect liver cells from damage.

**Table 1: Hepatoprotective activity of Medicinal Plants.**

Plant Name	Family	Active Compounds	Mechanism	Study Model
<b>Silybum marianum</b>	Asteraceae	Silymarin	Antioxidant, membrane stabilization	Clinical
<b>Curcuma longa</b>	Zingiberaceae	Curcumin	Anti-inflammatory, antioxidant	Animal
<b>Phyllanthus niruri</b>	Phyllanthaceae	Lignans	Antiviral, antioxidant	Animal

<b>Glycyrrhiza glabra</b>	Fabaceae	Glycyrrhizin	Anti-inflammatory, antiviral	Clinical
<b>Andrographis paniculata</b>	Acanthaceae	Andrographolide	Immunomodulatory	Animal
<b>Azadirachta indica</b>	Meliaceae	Nimbin	Antioxidant	Animal
<b>Ocimum sanctum</b>	Lamiaceae	Eugenol	Adaptogenic	Animal
<b>Picrorhiza kurroa</b>	Plantaginaceae	Picrosides	Antioxidant, hepatocyte protection	Animal
<b>Boerhavia diffusa</b>	Nyctaginaceae	Punarnavine	Anti-fibrotic	Animal
<b>Eclipta alba</b>	Asteraceae	Wedelolactone	Regenerative	Animal

## 6. HEPATOPROTECTIVE ACTIVITY OF MEDICINAL PLANTS

Each medicinal plant demonstrates hepatoprotective activity through multiple biochemical and molecular mechanisms, often involving synergistic effects of various phytoconstituents.

### 6.1 *Silybum marianum*

*Silybum marianum*, commonly known as milk thistle, is one of the most extensively studied hepatoprotective plants. Its primary bioactive component, silymarin—a mixture of flavonolignans including silybin, silydianin, and silychristin—confers hepatoprotection through multiple mechanisms. Silymarin stabilizes hepatocyte membranes, preventing toxin entry, enhances ribosomal protein synthesis to promote liver regeneration, and exhibits strong antioxidant activity by scavenging free radicals and increasing intracellular glutathione levels. Additionally, silymarin modulates inflammatory pathways, inhibiting NF- $\kappa$ B signaling and pro-inflammatory cytokines, and suppresses hepatic stellate cell activation, thereby reducing fibrosis. Preclinical studies in rodent models demonstrate that silymarin protects against liver injuries induced by carbon tetrachloride, acetaminophen, and ethanol, improving biochemical markers of liver function and histopathological architecture. Clinical trials in patients with alcoholic liver disease, viral hepatitis, and nonalcoholic fatty liver disease (NAFLD) report improved liver enzyme profiles, reduced oxidative stress, and enhanced liver function. Despite its efficacy and favorable safety profile, silymarin's variable bioavailability and phytochemical composition have prompted the development of standardized extracts and novel delivery systems to optimize therapeutic outcomes.<sup>[14-18]</sup>

### 6.2 *Curcuma longa*

*Curcuma longa*, or turmeric, is a widely used medicinal plant with significant hepatoprotective effects. Its main bioactive compound, curcumin, exerts hepatoprotection through multiple mechanisms. Curcumin scavenges reactive oxygen species (ROS), enhances endogenous antioxidant enzymes such as superoxide dismutase and catalase, and reduces lipid peroxidation, mitigating oxidative stress. It also modulates inflammatory pathways, including NF- $\kappa$ B and MAPK signaling, suppressing pro-inflammatory cytokines (TNF- $\alpha$ , IL-1 $\beta$ , IL-6). Additionally, curcumin inhibits hepatic stellate cell activation, preventing fibrosis, and improves lipid metabolism and insulin sensitivity, offering benefits in nonalcoholic fatty liver disease (NAFLD).

Preclinical studies have shown that curcumin protects against liver injury induced by carbon tetrachloride, acetaminophen, and ethanol in animal models, reducing biochemical markers of hepatotoxicity and histopathological damage. Clinical trials in patients with NAFLD and metabolic syndrome reported improvements in liver enzyme levels, hepatic steatosis, and oxidative stress markers. Despite its efficacy, curcumin's poor bioavailability has led to the development of enhanced formulations, including nanoparticles, liposomes, and phospholipid complexes, to improve absorption and therapeutic outcomes.<sup>[19-23]</sup>

### 6.3 *Phyllanthus niruri*

*Phyllanthus niruri* has been extensively studied for its hepatoprotective properties, demonstrating a multifaceted mechanism of action. The plant exhibits significant antiviral activity, particularly against hepatitis B and C viruses, by inhibiting viral replication and thereby reducing the progression of virus-induced liver damage. In addition, *P. niruri* exerts potent antioxidant effects, scavenging reactive oxygen species and enhancing endogenous antioxidant defenses, which protects hepatocytes from toxin-induced oxidative stress. Its anti-inflammatory activity further contributes to hepatoprotection by suppressing pro-inflammatory mediators and limiting hepatic inflammation. Clinical and experimental studies have also reported reductions in serum liver enzyme levels, including ALT, AST, and ALP, indicating stabilization of hepatocyte function. Collectively, these findings suggest that *Phyllanthus niruri* confers liver protection through an integrated antiviral, antioxidant, and anti-inflammatory mechanism, highlighting its therapeutic potential in the management of hepatic disorders.<sup>[24]</sup>

### 6.4 *Glycyrrhiza glabra*

*Glycyrrhiza glabra*, commonly known as licorice, is rich in glycyrrhizin, a bioactive compound with notable anti-inflammatory, antioxidant, and antiviral activities. Glycyrrhizin modulates immune responses and mitigates hepatic inflammation by suppressing pro-inflammatory cytokines, thereby protecting hepatocytes from immune-mediated damage. Clinically, licorice extracts have been employed in the management of chronic liver diseases, including viral hepatitis, demonstrating improvements in liver function and reductions in inflammatory markers. These findings highlight *G. glabra* as a promising hepatoprotective agent with both therapeutic and supportive roles in liver disease management.<sup>[25-26]</sup>

### 6.5 *Andrographis paniculata*

*Andrographis paniculata*, primarily through its bioactive diterpenoid andrographolide, has been widely investigated for hepatoprotective potential. Mechanistically, andrographolide exerts immunomodulatory effects by regulating cytokine production, alongside antioxidant activity that mitigates reactive oxygen species-mediated hepatocyte damage, and anti-inflammatory actions that limit hepatic tissue injury. Experimental models consistently show protection against chemically induced liver injury, with improvements in serum transaminases and other markers of liver function. However, despite promising preclinical evidence, clinical data remain limited, and the optimal dosing, bioavailability, and long-term safety in humans are not fully established. Furthermore, while andrographolide demonstrates multi-targeted hepatoprotection, most studies focus on acute or toxin-induced models, leaving its efficacy in chronic viral or metabolic liver diseases less well characterized. Future research should prioritize well-designed clinical trials, pharmacokinetic studies, and mechanistic exploration under disease-relevant conditions to validate its translational potential. Overall, *A. paniculata* represents a compelling hepatoprotective candidate, but its integration into evidence-based therapy requires further rigorous investigation.<sup>[27-31]</sup>

### 6.6 *Azadirachta indica*

*Azadirachta indica* (neem) has been widely investigated for its hepatoprotective potential, largely attributed to its strong antioxidant properties. The plant effectively reduces lipid peroxidation and enhances endogenous antioxidant enzyme systems, such as superoxide dismutase and catalase, thereby mitigating oxidative stress-induced hepatocellular damage. Experimental studies have demonstrated its ability to protect against toxin-induced liver injury and improve biochemical markers of hepatic function. However, despite consistent preclinical evidence, the precise molecular mechanisms underlying its hepatoprotective effects remain incompletely defined, and variability in extract composition poses challenges for reproducibility. Moreover, clinical evidence supporting its efficacy in human liver disorders is limited, restricting its current applicability in evidence-based practice. Therefore, while *A. indica* represents a promising natural hepatoprotective agent, further studies focusing on standardization, mechanistic validation, and well-controlled clinical trials are essential to substantiate its therapeutic potential.<sup>[33-37]</sup>

### 6.7 *Ocimum sanctum*

The plant enhances physiological resilience to stress, a factor increasingly linked to liver dysfunction, while its antioxidant activity reduces oxidative stress and lipid peroxidation in hepatocytes. Additionally, *O. sanctum* has been shown to support hepatic detoxification processes, thereby protecting liver tissue from chemical-induced damage. Preclinical studies consistently demonstrate improvements in liver enzyme profiles and

histopathological outcomes following toxic insult. However, despite these promising findings, clinical evidence remains sparse, and the mechanisms underlying its adaptogenic influence on liver health are not fully elucidated. Variability in phytochemical composition and lack of standardized dosing further limit its translational applicability. Consequently, while *O. sanctum* represents a potentially valuable hepatoprotective agent, more rigorous clinical and mechanistic studies are required to validate its role in liver disease management.<sup>[38-42]</sup>

### 6.8 *Picrorhiza kurroa*

*Picrorhiza kurroa* is a well-known hepatoprotective medicinal plant, primarily due to the presence of iridoid glycosides such as picrosides I and II. These bioactive compounds exhibit strong antioxidant activity, effectively reducing oxidative stress and protecting hepatocytes from toxin-induced injury. In addition to its cytoprotective effects, *P. kurroa* has been reported to enhance bile secretion, thereby supporting hepatic detoxification and improving overall liver function. Experimental studies consistently demonstrate its efficacy in ameliorating chemically induced liver damage and normalizing serum biochemical markers. However, despite substantial preclinical evidence, clinical validation remains limited, and variability in phytochemical content across preparations poses challenges for standardization. Furthermore, its choleric activity, while beneficial, requires careful evaluation in patients with biliary disorders. Thus, although *P. kurroa* represents a promising hepatoprotective agent, further well-designed clinical studies and pharmacological standardization are necessary to confirm its therapeutic utility.<sup>[44-47]</sup>

### 6.9 *Boerhavia diffusa*

*Boerhavia diffusa* is recognized for its notable antifibrotic and anti-inflammatory properties, contributing to its hepatoprotective potential in chronic liver disorders. The plant has been shown to inhibit excessive collagen deposition, a key pathological feature in hepatic fibrosis, thereby limiting progression toward cirrhosis. In addition, it promotes regeneration of damaged hepatocytes and supports restoration of normal liver architecture and function. Experimental studies further indicate improvements in biochemical and histopathological parameters following hepatic injury. However, despite these encouraging preclinical findings, the precise molecular pathways underlying its antifibrotic action remain incompletely understood, and robust clinical evidence is still lacking. Variability in phytochemical composition and insufficient standardization of extracts also limit reproducibility across studies. Therefore, while *B. diffusa* represents a promising candidate for managing chronic liver disease, further mechanistic investigations and well-controlled clinical trials are essential to establish its therapeutic relevance.<sup>[48-52]</sup>

### 6.10 *Eclipta alba*

*Eclipta alba* is widely recognized for its hepatoprotective and regenerative potential, primarily attributed to its ability to promote hepatocyte proliferation and support liver tissue repair. The plant has been shown to enhance liver cell regeneration following toxic injury, thereby contributing to the restoration of normal hepatic architecture and function. Improvements in serum liver enzyme levels, including ALT and AST, further indicate its role in stabilizing hepatocellular integrity. Experimental studies also suggest antioxidant and anti-inflammatory contributions to its overall hepatoprotective profile, which may synergistically support its regenerative effects. However, despite strong preclinical evidence, the molecular mechanisms governing its hepatocyte-stimulating activity remain incompletely elucidated, and clinical validation is limited. Additionally, variability in extract composition and lack of standardized formulations pose challenges for consistent therapeutic application. Thus, while *E. alba* represents a promising regenerative hepatoprotective agent, further mechanistic and clinical investigations are necessary to confirm its efficacy in human liver disorders.<sup>[53-57]</sup>

### 7. CLINICAL EVIDENCE

Clinical evidence supports the therapeutic potential of certain plant-derived compounds, particularly silymarin, in the management of liver disorders. Studies have shown improvements in liver enzyme levels, reduction in oxidative stress, and enhanced liver function in patients receiving herbal treatments.

However, most clinical studies are limited by small sample sizes, short duration, and lack of standardization. Therefore, large-scale, randomized controlled trials are necessary to establish the safety, efficacy, and dosage of these herbal agents.

### 8. NANOTECHNOLOGY AND MODERN ADVANCES

Recent advancements in nanotechnology have opened new avenues for enhancing the therapeutic potential of plant-derived hepatoprotective compounds. Many phytochemicals, including curcumin, silymarin, and andrographolide, exhibit limited clinical efficacy due to poor bioavailability, low aqueous solubility, and rapid metabolic clearance. Nanoparticle-based delivery systems, such as liposomes, polymeric nanoparticles, and solid lipid nanoparticles, offer solutions by improving the stability, solubility, and absorption of these bioactive molecules. Importantly, targeted delivery to liver tissue can be achieved, thereby enhancing therapeutic concentrations at the site of hepatic injury while minimizing systemic exposure. Preclinical studies have demonstrated that curcumin nanoparticles significantly increase oral bioavailability and antioxidant efficacy, whereas silymarin-loaded nanoparticles enhance hepatoprotective outcomes in toxin-induced liver injury models. Despite these promising results, challenges

remain in large-scale manufacturing, long-term safety, and regulatory approval. Nonetheless, nanotechnology represents a compelling strategy to overcome pharmacokinetic limitations and maximize the clinical potential of hepatoprotective phytochemicals, bridging the gap between traditional herbal medicine and modern evidence-based therapeutics.

### 9. LIMITATIONS AND CHALLENGES

Despite substantial preclinical evidence and traditional use, the clinical translation of medicinal plants for hepatoprotection faces several challenges. A major limitation is the lack of standardization in plant extracts, which leads to variability in the concentration of bioactive constituents. Environmental factors such as soil composition, climate, and harvesting conditions further contribute to inconsistent phytochemical profiles. Moreover, high-quality, large-scale clinical trials are limited, restricting evidence-based validation of efficacy and safety. Potential interactions with conventional drugs, along with uncertainties regarding optimal dosage, long-term safety, and tolerability, present additional barriers to clinical application. Addressing these limitations through rigorous research and standardized production processes is essential for developing reliable, reproducible, and clinically applicable plant-based hepatoprotective therapies.

### 10. Future Perspectives

Future research should aim to bridge the gap between traditional knowledge and modern evidence-based medicine. Key priorities include the isolation and detailed characterization of active phytochemicals, alongside elucidation of their molecular mechanisms of action in hepatoprotection. Large-scale, well-designed clinical trials are critical to establish efficacy, safety, and appropriate dosing guidelines. Standardization of formulations will ensure consistency and reproducibility across studies, enhancing clinical reliability. Furthermore, the integration of advanced drug delivery systems, such as nanoparticle-based platforms, holds significant promise for improving bioavailability, targeted delivery, and therapeutic outcomes. By combining traditional medicinal insights with modern pharmacological and technological approaches, researchers can accelerate the discovery and development of novel, effective hepatoprotective agents.

### 11. DISCUSSION

The present review highlights a diverse group of medicinal plants exhibiting significant hepatoprotective potential through multiple, often overlapping, pharmacological mechanisms. A common feature across all the discussed species is their strong antioxidant activity, which plays a central role in mitigating oxidative stress-induced hepatocellular injury. In addition, several plants such as *Phyllanthus niruri* and *Andrographis paniculata* demonstrate antiviral and immunomodulatory effects, making them particularly relevant in viral hepatitis-associated liver damage.

Others, including *Boerhavia diffusa* and *Eclipta alba*, extend their therapeutic relevance by promoting antifibrotic activity and hepatocyte regeneration, thereby addressing both the progression and recovery phases of liver injury.

Despite these promising pharmacological profiles, a critical analysis reveals a persistent gap between preclinical findings and clinical translation. Most evidence is derived from in vitro or animal models of toxin-induced hepatotoxicity, which may not fully replicate the complexity of human liver diseases such as chronic viral hepatitis, non-alcoholic fatty liver disease, or cirrhosis. Furthermore, variability in phytochemical composition, lack of standardized extracts, and insufficient pharmacokinetic and toxicity data limit reproducibility and therapeutic reliability. Safety concerns, such as those associated with long-term use of *Glycyrrhiza glabra*, further emphasize the need for cautious clinical application.

Another important observation is that hepatoprotection in these plants is rarely mediated by a single pathway; rather, it results from a synergistic interaction of antioxidant, anti-inflammatory, immunomodulatory, choleric, and regenerative mechanisms. This multi-targeted nature provides a strong pharmacological rationale for their potential use as adjunct therapies. However, it also complicates mechanistic elucidation and dose optimization, highlighting the need for advanced molecular studies and systems pharmacology approaches.

## 12. CONCLUSION

In conclusion, the medicinal plants reviewed demonstrate considerable hepatoprotective potential through diverse mechanisms, including antioxidant defense, immune modulation, antiviral activity, antifibrotic action, and hepatocyte regeneration. These multi-dimensional effects underscore their promise as complementary or alternative therapeutic agents in liver disease management. However, the current body of evidence is predominantly preclinical, and significant limitations remain in terms of clinical validation, standardization, and mechanistic clarity.

To bridge this gap, future research should focus on well-designed randomized clinical trials, identification and quantification of active phytoconstituents, and detailed pharmacokinetic and toxicological profiling. Integration of modern drug development approaches with traditional knowledge may facilitate the translation of these phytotherapeutic agents into evidence-based hepatoprotective therapies. Until such validation is achieved, their use should be considered supportive rather than definitive in the management of liver disorders.

## 13. REFERENCES

1. Ganong WF. Review of Medical Physiology. 26th ed. McGraw-Hill, 2020.
2. Parola M, Robino G. Oxidative stress-related molecules and liver fibrosis. *J Hepatol.*, 2001; 35(2): 297–306.
3. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment. *Hepatology*, 2016; 64(1): 73–84.
4. Czaja AJ. Hepatic inflammation and progressive liver fibrosis in chronic liver disease. *World J Gastroenterol.*, 2014; 20(10): 2515–32.
5. Teschke R. Drug-induced liver injury: Hepatotoxicity, mechanisms and management. *J Clin Transl Hepatol.*, 2019; 7(3): 189–206.
6. Sasidharan S, Chen Y, Saravanan D, Sundram KM, Latha LY. Extraction, isolation and characterization of bioactive compounds from plants' extracts. *African J Tradit Complement Altern Med.*, 2011; 8(1): 1–10.
7. Prince PSM, Menon VP. Hepatoprotective and antioxidant potential of natural compounds: Evidence from experimental studies. *Curr Drug Metab.*, 2021; 22(1): 65–78.
8. Kumar V, Sharma A, Singh R. Role of herbal drugs in the management of liver disorders. *J Pharmacogn Phytochem.*, 2019; 8(3): 111–8.
9. Jaeschke H, McGill MR, Ramachandran A. Oxidant stress, mitochondria, and cell death mechanisms in drug-induced liver injury. *Drug Metab Rev.*, 2012; 44(1): 88–106.
10. Li S, Tan HY, Wang N, et al. The role of oxidative stress in liver disease: Pathogenesis, prevention, and treatment. *Mediators Inflamm.*, 2015; 2015: 1–16.
11. Sharma S, Mishra P, Ghosh R. Oxidative stress and liver disease: Mechanistic insights. *Int J Hepatol.*, 2018; 2018: 1–10.
12. Albano E. Oxidative mechanisms in the pathogenesis of alcoholic liver disease. *Mol As.*
13. Pradhan SC, Girish C. Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine. *Indian J Med Res.*, 2006; 124: 491–504.
14. Surai PF. Silymarin as a natural antioxidant: An overview of the current evidence. *J Anim Physiol Anim Nutr (Berl.)*, 2015; 99: 739–55.
15. Flora K, Hahn M, Rosen H, Benner K. Milk thistle (*Silybum marianum*) for the therapy of liver disease. *Am J Gastroenterol.*, 1998; 93: 139–43.
16. Wellington K, Jarvis B. Silymarin: A review of pharmacological properties and therapeutic use in liver disease. *Drugs*, 2001; 61: 2035–63.
17. Loguercio C, Festi D. Silybin and the liver: From basic research to clinical practice. *World J Gastroenterol.*, 2011; 17: 2288–301.
18. Kim YJ, Lee HJ. Strategies for enhancing the bioavailability of silymarin. *Pharmaceutics*, 2021; 13: 1780.

19. Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin in liver disorders. *Biochem Pharmacol.*, 2009; 78: 1593–609.
20. Hewlings SJ, Kalman DS. Curcumin: A review of its effects on human health. *Foods*, 2017; 6: 92.
21. Wang R, Li C, Qian J, et al. Curcumin protects against non-alcoholic fatty liver disease through modulation of lipid metabolism and inflammatory signaling. *Front Pharmacol.*, 2020; 11: 580.
22. Panahi Y, et al. Curcumin efficacy in NAFLD: A randomized controlled trial. *Phytother Res.*, 2017; 31: 371–9.
23. Yallapu MM, et al. Curcumin-loaded nanoparticles: Targeted delivery and enhanced therapeutic outcomes. *J Nanobiotechnology*, 2012; 10: 36.
24. Caur M, Singh A, Singh P. Phyllanthus niruri: A review on its hepatoprotective, antiviral and antioxidant properties. *Journal of Ethnopharmacology*, 2019; 244: 112126. doi:10.1016/j.jep.2019.112126.
25. Wang ZY, Nixon DW. Licorice and cancer. *Nutr Cancer*, 2001; 39(1): 1–11. doi:10.1207/S15327914NC391\_1.
26. Armanini D, Fiore C, Mattarello MJ, Bielenberg J, Palermo M. Antiinflammatory and hepatoprotective effects of glycyrrhizin in chronic hepatitis. *J Ethnopharmacol.*, 2002; 81(1): 1–4. doi:10.1016/S0378-8741(02)00027-0.
27. Mishra S, Singh P, Tiwari S, et al. Hepatoprotective activity of *Andrographis paniculata* against carbon tetrachloride-induced liver toxicity in rats. *Phytomedicine*, 2007; 14(9): 601–608.
28. Chiang LC, Ng LT, Wang LH, et al. Immunomodulatory and hepatoprotective effects of *Andrographis paniculata* extract and andrographolide in mice. *Phytomedicine*, 2003; 10(6–7): 586–591.
29. Patil S, Jayakumar T, Rao R, et al. Antioxidant and hepatoprotective activity of andrographolide on experimental models of liver damage. *Indian J Exp Biol.*, 2011; 49(2): 100–106.
30. Jayakumar T, Hsieh CY, Lee JJ, Sheu JR. Hepatoprotective and antioxidant effects of *Andrographis paniculata*: A review. *J Basic Clin Physiol Pharmacol.*, 2013; 24(1): 1–12.
31. Coon JT, Ernst E. *Andrographis paniculata* in the treatment of upper respiratory tract infections: A systematic review of safety and efficacy. *Planta Med.*, 2004; 70(4): 293–298.
32. Subapriya R, Nagini S. Medicinal properties of neem leaves: a review. *Curr Med Chem Anticancer Agents*, 2005; 5(2): 149–156.
33. Sultana S, Ata A. Pharmacological properties of *Azadirachta indica* (neem) and its active constituents. *Phytother Res.*, 2008; 22(10): 1033–1042.
34. Venkataraman S, Shirwaikar A, Somasundaram A. Hepatoprotective effects of *Azadirachta indica* in carbon tetrachloride-induced liver injury in rats. *Indian J Pharmacol.*, 2009; 41(2): 88–91.
35. Biswas K, Chattopadhyay I, Banerjee RK, Bandyopadhyay U. Biological activities and medicinal properties of neem (*Azadirachta indica*). *Curr Sci.*, 2002; 82(11): 1336–1345.
36. Bhattacharya A, Mukherjee B, Bhattacharya S. Antioxidant and hepatoprotective effects of neem extract in experimental models of liver injury. *Phytother Res.*, 2004; 18(5): 389–393.
37. Alzohairy MA. Therapeutic role of neem (*Azadirachta indica*) in liver diseases: Recent advances. *J Herbal Med.*, 2021; 27: 100435.
38. Prakash P, Gupta N. Therapeutic uses of *Ocimum sanctum* (Tulsi) with a focus on liver protection: A systematic review. *Front Pharmacol.*, 2020; 11: 580289.
39. Mondal S, Mirdha BR, Mahapatra SC. The science behind sacredness of *Ocimum sanctum* (Tulsi): A review. *Indian J Physiol Pharmacol.*, 2009; 53(4): 291–304.
40. Kelm MA, Nair MG, Strasburg GM, DeWitt DL. Antioxidant and hepatoprotective properties of *Ocimum sanctum* leaf extract. *Phytomedicine*, 2000; 7(1): 7–13.
41. Singh S, Majumdar DK, Rehan HM. Evaluation of anti-stress, adaptogenic, and hepatoprotective activity of *Ocimum sanctum* Linn. *Indian J Exp Biol.*, 2001; 39(3): 203–207.
42. Astani A, Reichling J, Schnitzler P. Comparative study on the hepatoprotective and antioxidant effects of *Ocimum sanctum* and its major bioactive compounds. *Phytother Res.*, 2019; 33(12): 3120–3130.
43. Sharma RD, Sharma A. Hepatoprotective activity of *Picrorhiza kurroa* in carbon tetrachloride-induced liver damage in rats. *Indian J Med Res.*, 1992; 95: 123–129.
44. Sethi S, Kaur H, Singh P, et al. Hepatoprotective and antioxidant effects of picroside I and II from *Picrorhiza kurroa* in experimental models. *Phytother Res.*, 2004; 18(11): 903–907.
45. Thakur R, Sharma S, Kumar R, et al. Choleric and hepatoprotective effects of *Picrorhiza kurroa*: Mechanistic insights. *J Ethnopharmacol.*, 2019; 238: 111846.
46. Singh S, Suri A, Singh A. Clinical evaluation of *Picrorhiza kurroa* in patients with chronic hepatitis: A pilot study. *Phytomedicine*, 2009; 16(6–7): 597–601.
47. Raina RK, Agarwal RP, Agarwal SS. Standardization and hepatoprotective evaluation of *Picrorhiza kurroa* extract. *Pharmacognosy Rev.*, 2012; 6(11): 1–8.
48. Sagar S, Kumar A, Jha N. Hepatoprotective and antifibrotic activity of *Boerhavia diffusa* in carbon tetrachloride-induced liver injury in rats. *J Ethnopharmacol.*, 2012; 142(3): 666–673.
49. Suryakar AN, Bairagi S, Patil VR, et al. Protective effect of *Boerhavia diffusa* on experimentally induced hepatic fibrosis in rats. *Indian J Pharmacol.*, 2010; 42(5): 309–314.

50. Singh V, Katiyar CK, Yadav R. Role of *Boerhavia diffusa* in liver disorders: Mechanistic insights and therapeutic potential. *Phytother Res.*, 2019; 33(10): 2593–2605.
51. Khare CP. *Indian Medicinal Plants: An Illustrated Dictionary*. Berlin: Springer-Verlag, 2007; 86–87.
52. Sharma S, Gupta SK, Patnaik GK. Antifibrotic and hepatoprotective effects of *Boerhavia diffusa*: A review. *Pharmacogn Rev.*, 2016; 10(20): 88–94.
53. Panda S, Kar A. Hepatoprotective activity of *Eclipta alba* against paracetamol-induced hepatotoxicity in rats. *J Ethnopharmacol.*, 2007; 111(2): 227–231.
54. Shukla S, Mehta A, Kumar S. Antioxidant and hepatoprotective effects of *Eclipta alba* on carbon tetrachloride-induced liver injury in rats. *Phytomedicine*, 2011; 18(4): 322–329.
55. Ramesh P, Pattabiraman TN. Effect of *Eclipta alba* on liver regeneration and hepatocyte proliferation: An experimental study in rats. *Indian J Exp Biol.*, 2005; 43(12): 1160–1165.
56. Chatterjee TK. *The Treatise on Indian Medicinal Plants*. New Delhi: National Institute of Science Communication, 2000; 125–127.
57. Kumar S, Choudhary S, Saxena RC. Hepatoprotective and antioxidant potential of *Eclipta alba*: A review. *Pharmacogn Rev.*, 2010; 4(8): 148–154.